Deep Tech Startups

Dyna develops general-purpose robots powered by foundation models that adapt across environments and learn new skills rapidly, with deployment across a fleet that continuously improves.

7 investors

Edgescale builds AI "systems-in-a-box" that deploy AI to operational environments such as manufacturing, utilities, and critical infrastructure, connecting isolated edge devices with modern software while keeping critical data private. It targets industrial and infrastructure operators seeking to apply AI at the edge where work physically happens.

7 investors

Elemind makes a wearable neurotech sleep headband that measures EEG brain signals and delivers phase-locked acoustic stimulation to help users fall asleep faster and return to sleep after waking. The device pairs with a companion app for headband control and sleep tracking, and is sold to consumers with sleep difficulties.

7 investors

Emerald AI develops software to enable power flexibility in data centers by orchestrating power demand in response to grid needs. The company applies AI and machine learning to optimize cloud computing systems for grid-aware operations.

7 investors

Formation Bio develops drugs through partnerships with health systems, academic medical centers, and research sites, focusing on clinical trials in dermatology, rheumatology, and cardiometabolic diseases. The company provides trial management infrastructure, monitoring, technology, and enrollment support to accelerate drug development.

7 investors

GITAI develops robotic technologies for space exploration, specializing in robotic solutions for the construction and maintenance of satellites, lunar settlements, and planetary infrastructure.

7 investors

Greenjets is a technology company developing electric propulsion products, initially targeting the drone market. It spun out of Blue Bear Systems Research as an independent company in 2022.

7 investors

Humane Genomics develops oncolytic viral therapies designed to selectively target and kill cancer cells using engineered RNA viruses, particularly Vesicular Stomatitis Virus. The company leverages a computational platform for viral genome design and engineering to create cancer treatments with improved safety, efficacy, and manufacturing efficiency.

7 investors

Iambic develops AI technologies for drug discovery, using a high-throughput experimental platform to design small-molecule medicines and advance a pipeline of clinical candidates for cancers such as HER2-driven, breast, and ovarian tumors. It serves the pharmaceutical industry through both its own drug pipeline and partnerships.

7 investors

Immusoft develops a cell therapy platform called Immune System Programming (ISP) that engineers a patient's B cells into plasma cells that produce therapeutic proteins after being infused back into the patient. The company focuses on personalized protein therapeutics for patients.

7 investors

Kebotix uses artificial intelligence, machine learning, and laboratory automation to discover and develop new materials and molecules. The company serves product manufacturers and industries seeking high-performance, environmentally friendly materials.

7 investors

Kyoto Fusioneering develops fusion energy technology and related engineering solutions to enable carbon-neutral power generation and advanced chemical processes such as hydrogen production and carbon capture. The company conducts research in partnership with Kyoto University and other institutions to commercialize fusion energy applications.

7 investors

Kytopen develops non-viral gene delivery technology called Flowfect that combines fluid flow with electric fields to deliver payloads such as mRNA, DNA, and CRISPR Cas9 RNP into cells for high-throughput transfection. Its platforms serve cell therapy researchers and developers, supporting drug discovery, process optimization, and scaling from small-volume experiments to manufacturing.

7 investors

Lunar Outpost builds robotic infrastructure, lunar rovers, and space resource systems to support human exploration and commerce on the Moon and other planetary bodies. Its products include the crewed/uncrewed Eagle lunar vehicle and the MAPP mobility rover for operations in harsh planetary environments.

7 investors

Modern Intelligence builds artificial intelligence software for defense applications, providing target analysis and decision-making from small data samples. Its hardware- and software-agnostic AI integrates across platforms and is aimed at commercial industry and defense customers.

7 investors

Moderna develops mRNA-based medicines for infectious and serious diseases using its proprietary mRNA platform and design technology.

7 investors

Neumora is a clinical research company developing investigational medications, with a focus on conducting clinical trials to obtain regulatory approval and make treatments available to patients.

7 investors

North Vector Dynamics is a Canadian defence technology company developing precision interception, autonomy, and advanced propulsion systems, including counter-UAS solutions and hypersonics. It aims to build a full-spectrum sovereign missile capability for Canada and its allies, partnering with defence primes and systems integrators.

7 investors

Orbion Space Technology builds Hall-effect electric propulsion systems for small-satellite constellations, providing integrated thrusters, power processing units, and propellant management for in-space maneuvers. Its AS9100D-certified hardware supports functions like collision avoidance, drag compensation, and orbit transfer for satellite operators.

7 investors

Outpace Bio develops engineered protein technologies and cell therapies to treat solid tumors, focusing on protein design and T cell engineering to improve cancer treatment efficacy and safety.

7 investors

Outpost is an advisory and operations team of space-industry veterans that helps space companies grow from concept through scale-up, acquisition, and IPO. It draws on experience flying spacecraft, building in-space manufacturing, and human spaceflight to apply space technology to problems on Earth.

7 investors

ParcelBio develops APEXm, a proprietary mRNA platform that enhances protein expression for longer-lasting therapeutic effect compared to conventional mRNA technologies. The platform targets autoimmune disease, oncology, and therapeutic protein replacement applications.

7 investors

Pixxel builds hyperspectral satellite systems and software to monitor Earth's ecosystems, resources, and atmosphere for environmental management and climate action. The company serves decision-makers in agriculture, water quality monitoring, and sustainability sectors across the globe.

7 investors

Plexium is a targeted protein degradation company developing small molecule therapeutics for treating diseases with high unmet medical needs using their proprietary DELTA Discovery platform.

7 investors